Month: March 2016

The Cresemba Candidemia Gamble – Rien Ne Va Plus

Posted on by — 1 Comment ↓

Isavuconazole is a potent triazole; like Voriconazole, it has garnered an indication for invasive aspergillosis. However, it failed where other azole antifungals succeeded: in a pivotal trial, not yet published, the drug was inferior to Caspofungin in the treatment of invasive candidiasis/candidemia in non-neutropenic patients [1]. To provide some background: in Continue reading The Cresemba Candidemia Gamble – Rien Ne Va Plus→

Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Posted on by — No Comments ↓

Sometimes one comes across a particularly well-written policy document which summarizes the status quo of antimicrobial resistance by connecting and synthesizing data from all kinds of sources into a coherent framework. The 2015 OECD Report on Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action Continue reading Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action→

Recent Sepsis Literature

Posted on by — No Comments ↓

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has defied causal intervention but for which symptomatic treatment has improved Continue reading Recent Sepsis Literature→